Avicanna Inc. (AVCN) Q4 2023 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Avicanna Inc.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.609 -- 00:00:02.391 which yielded 51% 00:00:02.391 -- 00:00:05.573 growth in our finished products sold in Canada. 00:00:05.573 -- 00:00:07.995 This expansion was increased 00:00:07.995 -- 00:00:12.358 through the number of commercial SKUs, through the number of commercial listings, and 00:00:12.358 -- 00:00:16.441 the fact that we have now launched products across seven different medical platforms, 00:00:16.441 -- 00:00:18.703 including our own MyMedic. 00:00:18.703 -- 00:00:24.050 Our R&D and clinical efforts Sustaining our intellectual property has also expanded 00:00:24.050 -- 00:00:28.411 and has led to two new strategic collaborations with two separate international pharmaceutical 00:00:28.411 -- 00:00:33.753 companies and has led to the marketing authorization of our first pharmaceutical 00:00:33.753 -- 00:00:38.874 product through Invima called Trunerex, which was recently announced 00:00:38.874 -- 00:00:41.465 during early Q1 2024. 00:00:46.243 -- 00:00:51.367 An overview of MyMedi. So on August 2nd, 2023, we proudly launched our new medical 00:00:51.367 -- 00:00:54.330 cannabis platform called MyMedi.ca. 00:00:54.330 -- 00:00:58.633 As mentioned, this was arrived from the acquisition of the Sharpless Drug Mart division. 00:00:58.633 -- 00:01:04.057 MyMedi.ca features a diverse portfolio of products from Avicana and 15 licensed producers 00:01:04.057 -- 00:01:08.657 here in Canada. The platform is available nationwide and led by our pharmacists, led 00:01:08.657 -- 00:01:13.658 bilingual patient support programs, in addition to educational resources for the 00:01:13.658 -- 00:01:18.899 medical community, all of which is to facilitate the incorporation of medical cannabis 00:01:18.899 -- 00:01:23.380 into the healthcare regimen. MyMedi is oper...